Pretreatment with valproic acid, a histone deacetylase inhibitor, enhances the sensitivity of the peripheral blood micronucleus assay in rodents

2013 ◽  
Vol 751 (1) ◽  
pp. 19-26 ◽  
Author(s):  
T. Ahmad ◽  
K. Shekh ◽  
S. Khan ◽  
A. Vikram ◽  
L. Yadav ◽  
...  
Keyword(s):  
Valproic Acid ◽  
Histone Deacetylase ◽  
Peripheral Blood ◽  
Histone Deacetylase Inhibitor ◽  
Micronucleus Assay ◽  
Deacetylase Inhibitor

scholarly journals Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia

Haematologica ◽  
2007 ◽  
Vol 92 (4) ◽  
pp. 542-545 ◽  
Author(s):  
G. Bug ◽  
K. Schwarz ◽  
C. Schoch ◽  
M. Kampfmann ◽  
R. Henschler ◽  
...  
Keyword(s):  
Valproic Acid ◽  
Acute Myeloid Leukemia ◽  
Progenitor Cells ◽  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Myeloid Leukemia ◽  
Deacetylase Inhibitor ◽  
Acute Myeloid

scholarly journals Radioprotective effects of valproic acid, a histone deacetylase inhibitor, in the rat brain

2014 ◽  
Vol 3 (1) ◽  
pp. 63-69 ◽  
Author(s):  
YONG ZHOU ◽  
JUNJIE NIU ◽  
SHUPENG LI ◽  
HUAYING HOU ◽  
YING XU ◽  
...  
Keyword(s):  
Valproic Acid ◽  
Rat Brain ◽  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Deacetylase Inhibitor

scholarly journals Association of Valproic Acid Use, a Potent Histone Deacetylase Inhibitor, and Melanoma Risk

2020 ◽  
Vol 140 (12) ◽  
pp. 2353-2358
Author(s):  
Afton Chavez ◽  
Charles P. Quesenberry ◽  
Jeanne Darbinian ◽  
Maryam M. Asgari
Keyword(s):  
Valproic Acid ◽  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Melanoma Risk ◽  
Deacetylase Inhibitor

Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells

Blood ◽  
2002 ◽  
Vol 99 (6) ◽  
pp. 2248-2251 ◽  
Author(s):  
Masaki Kitazono ◽  
Vemulkonda Koneti Rao ◽  
Rob Robey ◽  
Takashi Aikou ◽  
Susan Bates ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
Peripheral Blood ◽  
Histone Deacetylase Inhibitor ◽  
Mononuclear Cells ◽  
Histone H3 ◽  
Hematopoietic Cells ◽  
Adenovirus Infection ◽  
Peripheral Blood Stem Cells ◽  
Peripheral Blood Mononuclear ◽  
Deacetylase Inhibitor

Abstract Adenovirus infection of hematopoietic cells frequently requires high virus concentrations and long incubation times to obtain moderate infection levels because these cells have low levels of Coxsackie and adenovirus receptor (CAR) and αv integrin. The effect of treatment with FR901228 (depsipeptide), a histone deacetylase inhibitor in phase 2 clinical trials, was studied in K562 cells, granulocyte–colony-stimulating factor–mobilized peripheral blood mononuclear cells (PBMCs), and CD34+ peripheral blood stem cells (PBSCs). FR901228 increased CAR and αvintegrin RNA levels and histone H3 acetylation. FR901228 treatment before adenovirus infection was associated with at least a 10-fold increase in transgene expression from a β-galactosidase–expressing adenoviral vector. More than 80% of the PBMCs or CD34+ PBSCs from 7 different donors were β-galactosidase–positive after adenovirus infection with a multiplicity of infection of 10 for 60 minutes. Increased CAR, αv integrin, and acetylated histone H3 levels were observed in PBMCs from a patient treated with FR901228. These studies suggest that FR901228 can increase the efficiency of adenoviral infection in hematopoietic cells.

Sign in / Sign up

Export Citation Format

Share Document